Histocell is a private biopharmaceutical company focused on developing, manufacturing and commercializing novel medical devices, active ingredients and cell therapy medications for regenerative medicine. The proprietary technology of Histocell is focused on the repair of damaged tissues exposed to oxidative stress and proinflammatory environments. Our products are protected by strong intellectual property with 55 granted patents to date. Histocell counts on a highly qualified multidisciplinary team of professionals from academic and industry fields, including 7 PhDs. The company has a GMP facility for advanced therapy medicinal products development and manufacturing, certified by the Spanish Drug Agency/European Medicines Agency (AEMPS/EMA) from 2011. In addition, Histocell also has a medical devices production plant that is ISO-13485 certified.
Our role in NABIHEAL
Within the project, Histocell participates in WP1 and WP4, contributing to the development and manufacturing of advanced medical devices for chronic hard-to-heal wounds. Histocell will focus on the control of wound bioburden while activating the wound healing process, through an evolution of Histocell existing biomaterials with proven healing capacity. In addition, Histocell will co-lead with Nanomol Technologies WP7, managing the protection of intellectual property, defining the exploitation strategy and seeking additional financing tools after the completion of the project.
Our team for NABIHEAL
Begoña Castro Feo
WP1 & WP4 Lead, Final Product form (Task 4.3)
Eva González Lavado
WP7 Lead, IPR and Exploitation